Wnt Signaling in Bone Metabolism

Overview

Journal J Bone Miner Metab

Specialty Endocrinology

Date 2009 Apr 1

PMID 19333681

Citations 64

Authors

Takuo Kubota

Toshimi Michigami

Keiichi Ozono

Affiliations

Soon will be listed here.

Abstract

A variety of in vivo models have increased understanding of the role of Wnt signaling in bone since mutations in the LRP5 gene were found in human bone disorders. Canonical Wnt signaling encourages mesenchymal progenitor cells to differentiate into osteoblasts. In osteoblasts, Wnt pathway also promotes proliferation and mineralization, while blocks apoptosis and osteoclastogenesis by increasing the OPG/RANKL ratio. Lrp6-mediated signaling in osteoblasts may regulate osteoclastogenesis. However, the role of canonical Wnt signaling in osteoclasts remains unknown, and our understanding of the role of non-canonical Wnt signaling in bone biology is also not sufficient. As to pharmacological intervention, many levels may be considered to target in Wnt signaling pathway, although tumorigenicity and toxicity to other tissues are important. Mesd might be one of target molecules to increase the quantity of LRP5/6 in the plasma membrane. Since sclerostin is almost exclusively expressed in osteocytes, abrogating sclerostin is the most promising design.

Citing Articles

In-silico analysis predicts disruption of normal angiogenesis as a causative factor in osteoporosis pathogenesis.

James R, Subramanyam K, Payva F, E A, Tv V, Sivaramakrishnan V BMC Genom Data. 2024; 25(1):85.

PMID: 39379846 PMC: 11460074. DOI: 10.1186/s12863-024-01269-z.

Bone canonical Wnt signaling is downregulated in type 2 diabetes and associates with higher advanced glycation end-products (AGEs) content and reduced bone strength.

Leanza G, Cannata F, Faraj M, Pedone C, Viola V, Tramontana F Elife. 2024; 12.

PMID: 38598270 PMC: 11006415. DOI: 10.7554/eLife.90437.

Prevention and Co-Management of Breast Cancer-Related Osteoporosis Using Resveratrol.

Meyer C, Brockmueller A, Buhrmann C, Shakibaei M Nutrients. 2024; 16(5).

PMID: 38474838 PMC: 10934808. DOI: 10.3390/nu16050708.

IMPACT OF GRAVES' DISEASE AND ANTITHYROID DRUG THERAPY ON BONE MINERAL DENSITY - PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL RELEVANCE.

Mudri D, Kizivat T, Smolic M, Mihaljevic I, Smolic R, Lucic N Acta Clin Croat. 2023; 61(3):496-504.

PMID: 37492357 PMC: 10364114. DOI: 10.20471/acc.2022.61.03.15.

Hyperthyroidism and Wnt Signaling Pathway: Influence on Bone Remodeling.

Mudri D, Curcic I, Mestrovic L, Mihaljevic I, Kizivat T Metabolites. 2023; 13(2).

PMID: 36837860 PMC: 9968154. DOI: 10.3390/metabo13020241.

References

Kugimiya F, Kawaguchi H, Ohba S, Kawamura N, Hirata M, Chikuda H . GSK-3beta controls osteogenesis through regulating Runx2 activity. PLoS One. 2007; 2(9):e837. PMC: 1950686. DOI: 10.1371/journal.pone.0000837. View

Clement-Lacroix P, Ai M, Morvan F, Roman-Roman S, Vayssiere B, Belleville C . Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A. 2005; 102(48):17406-11. PMC: 1297659. DOI: 10.1073/pnas.0505259102. View

Little R, Carulli J, Mastro R, Dupuis J, Osborne M, Folz C . A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2001; 70(1):11-9. PMC: 419982. DOI: 10.1086/338450. View

Richards J, Rivadeneira F, Inouye M, Pastinen T, Soranzo N, Wilson S . Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet. 2008; 371(9623):1505-12. PMC: 2679414. DOI: 10.1016/S0140-6736(08)60599-1. View

Li X, Liu P, Liu W, Maye P, Zhang J, Zhang Y . Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet. 2005; 37(9):945-52. DOI: 10.1038/ng1614. View

Kang S, Bennett C, Gerin I, Rapp L, Hankenson K, MacDougald O . Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem. 2007; 282(19):14515-24. DOI: 10.1074/jbc.M700030200. View

Clevers H . Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-80. DOI: 10.1016/j.cell.2006.10.018. View

Kokubu C, Heinzmann U, Kokubu T, Sakai N, Kubota T, Kawai M . Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis. Development. 2004; 131(21):5469-80. DOI: 10.1242/dev.01405. View

Moon R, Kohn A, De Ferrari G, Kaykas A . WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004; 5(9):691-701. DOI: 10.1038/nrg1427. View

10.

Ali A, Hoeflich K, Woodgett J . Glycogen synthase kinase-3: properties, functions, and regulation. Chem Rev. 2001; 101(8):2527-40. DOI: 10.1021/cr000110o. View

11.

Brunkow M, Gardner J, Van Ness J, Paeper B, Kovacevich B, Proll S . Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68(3):577-89. PMC: 1274471. DOI: 10.1086/318811. View

12.

Li X, Ominsky M, Niu Q, Sun N, Daugherty B, DAgostin D . Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23(6):860-9. DOI: 10.1359/jbmr.080216. View

13.

Huang H, He X . Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol. 2008; 20(2):119-25. PMC: 2390924. DOI: 10.1016/j.ceb.2008.01.009. View

14.

Gaur T, Lengner C, Hovhannisyan H, Bhat R, Bodine P, Komm B . Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem. 2005; 280(39):33132-40. DOI: 10.1074/jbc.M500608200. View

15.

Ross S, Hemati N, Longo K, Bennett C, Lucas P, Erickson R . Inhibition of adipogenesis by Wnt signaling. Science. 2000; 289(5481):950-3. DOI: 10.1126/science.289.5481.950. View

16.

Semenov M, Tamai K, He X . SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005; 280(29):26770-5. DOI: 10.1074/jbc.M504308200. View

17.

Van Wesenbeeck L, Cleiren E, Gram J, Beals R, Benichou O, Scopelliti D . Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet. 2003; 72(3):763-71. PMC: 1180253. DOI: 10.1086/368277. View

18.

van Meurs J, Trikalinos T, Ralston S, Balcells S, Brandi M, Brixen K . Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA. 2008; 299(11):1277-90. PMC: 3282142. DOI: 10.1001/jama.299.11.1277. View

19.

Kulkarni N, Onyia J, Zeng Q, Tian X, Liu M, Halladay D . Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res. 2006; 21(6):910-20. DOI: 10.1359/jbmr.060316. View

20.

Winkler D, Sutherland M, Geoghegan J, Yu C, Hayes T, Skonier J . Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22(23):6267-76. PMC: 291840. DOI: 10.1093/emboj/cdg599. View